First Patient Enrolled in Biodesix and Addario Lung Cancer Medical Institute Study Aiming to Predict Patient Survival Using a Blood-based Biomarker

SAN CARLOS, Calif. and BOULDER, Colo.: SAN CARLOS, Calif. and BOULDER, Colo., May 26, 2021 /PRNewswire/ -- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, and Addario Lung Cancer Medical Institute (ALCMI) today announced they will present on the progress of "Biomarker...

Click to view original post